N/A N=52 Mindfulness and Neural Cardiovascular Control in Humans
Elevated Blood Pressure
Primary: Muscle Sympathetic Nerve Activity — -2; -1 bursts per minute — p=0.51
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Impact of Symbiofilm On Nasal Microbiota
Rhinosinusitis Chronic · Microbiome
Primary: Comparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2) — 2.041; 2.114 Shannon Index — p=0.908
N/A N=34 Comparative Evaluation of External Chest Wall Fixator Treatment Effectiveness in Patients With Rib Fractures
Rib Fractures · Trauma
Primary: Pain Level — 1.79; 2.85 score on a scale
N/A N=150 Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular
Peripheral Arterial Disease
Primary: Primary Efficacy Endpoint: Freedom From MALE — 144 Participants
N/A N=27 A Remote Evaluation of NAVIFY Oncology Hub Using Clinical Simulation
Oncology
Primary: System Usability Scale (SUS) — 82 score on SUS
N/A N=48 Group Depression Treatment for Autistic Youth
Autism Spectrum Disorder · Depression · Suicidal Ideation
Primary: Change in Severity of Adolescent Depressive Symptoms, Self-report — 8.14 T-score
N/A N=5 Validation of Point Partial User Needs With Partial Finger Amputees
Amputation; Traumatic, Hand
Primary: VAL-1: System Comfort Validation Test — 100 % of participants who Passed test
N/A N=35 Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse
Chronic Pain · Problematic Opioid Use
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) - Pain Behavior — 66.7; 66.0; 64.3; 66.8 units on a scale
N/A N=30 Headgear Accessory for Exercise-Induced Laryngeal Obstruction Studies
Exercise-Induced Laryngeal Obstruction
Primary: Percentage of Participants With Continuous Laryngoscopy During Exercise Tests — 100 percentage of participants
N/A N=338,718 Developing and Testing a COVID-19 Vaccination Acceptance Intervention
COVID-19 Vaccination
Primary: Receipt of Any Dose COVID-19 Vaccination — 57621; 65407 Participants — p=0.202
Phase 2 N=45 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Acute Graft Versus Host Disease
Primary: Phase I: Measurement of Pharmacokinetic (PK) Parameter, AUClast, in aGvHD and SR-aGvHD Patients — 252; 372; 154; 239 ng*hr/mL
Phase 1 N=39 Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
Resectable Soft Tissue Sarcoma · Soft Tissue Sarcoma
Primary: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dosage for Each Cohort — 5; NA times per week of 125mg PO
Phase 3 N=99 A Home-based Module to Promote Mindful Breathing Awareness for COPD Patients
COPD
Primary: Change in Chronic Respiratory Disease Questionnaire (CRQ)- Dyspnea Score — 0.68; 0.71; 0.34; 0.83 score on a scale
N/A N=1,065 EnSite Precision Observational Study
Cardiac Arrhythmia
Primary: Rate of Acute Success Based on Pre-defined Procedural Endpoints — 901 Participants
Phase 4 N=100 Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
Unresectable Non-small Cell Lung Cancer (NSCLC)
Primary: Number and Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI) — 74; 21; 74; 21 Participants